AI assistant
ECHOIQ LIMITED — Board/Management Information 2022
Sep 12, 2022
64833_rns_2022-09-12_95abfce4-0c31-4caf-9fa9-bd4ea344cbe2.pdf
Board/Management Information
Open in viewerOpens in your device viewer
ASX: EIQ RELEASE
13 September, 2022
==> picture [146 x 26] intentionally omitted <==
ECHO IQ USA PRESIDENT APPOINTED TO LEAD US COMMERCIALISATION
Highlights
-
Highly experienced medical technology leader to spearhead US market development
-
Seasoned healthcare executive to join Echo IQ from 1 October, 2022 based in Austin, TX
Sydney: AI and Medical Technology company Echo IQ (the Company) (ASX:EIQ) is pleased to announce the appointment of Donald Fowler to the newly created position of President, Echo IQ USA.
Don brings more than 30 years of executive leadership in high technology medical systems to the company, with particular expertise in business scale-up and commercialisation. He spent 26 years working for Siemens Healthcare (USA), a global leader in medical imaging, laboratory diagnostics and healthcare information technology. He subsequently joined Toshiba (America) Medical Systems, one of the world’s pre-eminent producers and distributors of diagnostic imaging systems, where he went on to hold roles as President, CEO and Board Director.
Don’s technical knowledge, industry experience and network of leading decision-makers in Echo IQ’s priority channels (from ASCs and hospitals, to diagnostic labs and specialist physicians) is expected to help the company fast-track the roll-out of its novel AI-backed solutions for structural heart health.
Deon Strydom, Echo IQ’s Chief Commercial Officer said: “We are excited that our first US appointment is someone of the calibre and experience of Don Fowler. Don is highly regarded and respected in the industry for his professionalism as well as technical and commercial skills. We look forward to welcoming him to the team from 1 October, 2022.”
- ENDS -
Authorised for release by the Board of Directors of Echo IQ Limited.
Media Enquiries: Philip Woolff, Chief Operating Officer [email protected] / [email protected] / +61 (0)490 030 620
Investor Enquiries: Andrew Grover, Executive Chair [email protected] / [email protected]
ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.
ECHOIQ Limited / ABN: 48 142 353 +61 2 9159 3719 / echoiq.ai 404/309 George Street, Sydney NSW 2000, Australia